July 9, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on Solvonis Therapeutics PLC (LSE: SVNS) titled, “Pursuing Acute Intervention Rather Than Chronic Treatment of High-Burden CNS Conditions”. The report can be accessed here.
Solvonis Therapeutics PLC (LSE: SVNS) is a London-headquartered, clinical-stage biopharmaceutical company focused exclusively on high-burden central nervous system (CNS) disorders across two strategic pillars—addiction and psychiatry—with early discovery extending toward neurology. The company was formerly Graft Polymer (UK) PLC, a polymer and drug delivery business, and was renamed Solvonis in January 2025 as part of a wholesale repositioning toward CNS therapeutics. That repositioning was anchored by the May 2025 acquisition of Awakn Life Sciences Corp., the originator of the ketamine-assisted therapy program for alcohol use disorder (AUD) that now forms the company’s leading assets.
Solvonis is developing acute, durable interventions for high-burden CNS disorders rather than chronic maintenance therapies across the full development spectrum. Its clinical-stage programs are anchored by ketamine’s glutamatergic, an NMDA receptor antagonist mechanism, which is thought to induce a transient period of enhanced neuroplasticity during which structured psychotherapy may help remodel the neural circuits underlying craving and addictive behavior. The company’s lead indication is AUD, one of the most prevalent substance use disorders in the US and Europe, associated with an annual economic burden estimated in the hundreds of billions of dollars and served by pharmacological treatment options that have seen little innovation in decades.
Beyond its clinical-stage AUD programs, Solvonis owns an AI-enabled drug discovery platform underpinning a proprietary preclinical pipeline, the first outputs of which are SVN-114, a SERT/DAT/NET modulation for PTSD and other psychiatric indications, and SVN-015, a SERT/DAT blockade for stimulant use disorder (SUD).
Solvonis is positioned as a late clinical-stage company targeting high-burden CNS disorders with a microcap valuation. The three most important catalysts for Solvonis over the next two years include initiating the SVN-002 Phase 2b trial in the US, pursuing a potential US listing to gain greater access to US capital to help support SVN-002 advancement, and the SVN-001 readout in 2028.
About WTR. Modernizing Investor Engagement Through Research-Driven Strategies. At WTR, we help companies and investors connect by creating expert information flow and strategies that are the foundation of a successful modern investor engagement platform. Our analysts and capital markets professionals bring decades of unrivaled Wall Street experience and insight to a new digital world of investor communications and engagement. Our research and investor content is open for everyone to access and distributed across traditional research aggregators like Bloomberg, FactSet, etc., proprietary direct distribution lists, social media, search engines, and our website. As a result, every institutional and retail investor has equal access to our high-quality company research. Our mission is to help companies proactively reach investors while bringing investors a consistent flow of quality information to help them understand our clients’ businesses, industries, and the investment opportunities they present.
